A Multicenter, Randomized, Double-Blind, Parallel-Group Study to Assess the Efficacy and Safety of Oral Etrasimod as Induction and Maintenance Therapy for Moderately to Severely Active Crohn's Disease
Latest Information Update: 08 May 2024
At a glance
- Drugs Etrasimod (Primary)
- Indications Crohn's disease
- Focus Pharmacokinetics; Therapeutic Use
- Acronyms CULTIVATE
- Sponsors Arena Pharmaceuticals; Pfizer
- 01 May 2024 Planned End Date changed from 3 Jul 2029 to 8 Aug 2029.
- 01 May 2024 Planned primary completion date changed from 10 Jun 2025 to 16 Jul 2025.
- 28 Mar 2024 Planned number of patients changed from 1265 to 1325.